| Population 2015 |
54 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
27 |
(16–40) |
49 |
(30–74) |
| Mortality (HIV+TB only) |
4.8 |
(3.5–6.5) |
9 |
(6.4–12) |
| Incidence (includes HIV+TB) |
197 |
(144–258) |
365 |
(267–479) |
| Incidence (HIV+TB only) |
17 |
(11–25) |
32 |
(21–47) |
| Incidence (MDR/RR-TB)** |
14 |
(8.9–18) |
26 |
(17–33) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
6 |
(2.4–9.6) |
66 |
(35–97) |
72 |
(38–106) |
| Males |
7.7 |
(4.8–11) |
117 |
(87–147) |
125 |
(92–158) |
| Total |
14 |
(9.4–18) |
183 |
(152–214) |
197 |
(144–258) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
140 700 |
| Total new and relapse |
138 447 |
| - % tested with rapid diagnostics at time of diagnosis |
22% |
| - % with known HIV status |
65% |
| - % pulmonary |
88% |
| - % bacteriologically confirmed among pulmonary |
39% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
70% (54–96) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.16 (0.1–0.26) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
7 918 |
9% |
| - on antiretroviral therapy |
3 034 |
38% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
9 000
(6 400–12 000) |
| Estimated % of TB cases with MDR/RR-TB |
5.1% (3.2–7) |
27% (15–39) |
|
| % notified tested for rifampicin resistance |
7% |
46% |
14 599 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
43 |
| Laboratory-confirmed cases |
MDR/RR-TB: 2 793, XDR-TB: 11 |
| Patients started on treatment **** |
MDR/RR-TB: 2 207, XDR-TB: 7 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
87% |
135 984 |
| Previously treated cases, excluding relapse, registered in 2014 |
73% |
3 677 |
| HIV-positive TB cases, all types, registered in 2014 |
70% |
10 782 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
83% |
667 |
| XDR-TB cases started on second-line treatment in 2013 |
|
|
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
10% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
3.6% (3.3–3.9) |
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
69 |
| Funding source: 21% domestic, 52% international, 28% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |